Previous studies have shown that dabrafenib or vemurafenib, a selective BRAF inhibitor, significantly improves progression-free survival (PFS), clinical response rate (RR), and overall survival (OS) compared to chemotherapy in BRAF-mutant melanoma patients [9,10]. Here, BRAF is linked to melanoma.